- Algernon (AGN) has submitted a meeting request to the FDA for its DMT clinical stroke research program
- Algernon seeks guidance on DMT and constraint-induced movement therapy to treat upper-limb dysfunction in stroke patients
- The company has filed provisional patents for new forms of DMT and combination therapy between DMT and CIMT
- Algernon is a drug re-purposing company that investigates approved drugs for new disease applications
- Algernon Pharmaceuticals (AGN) is up 6.35 per cent, trading at C$0.335 per share as of 1:25 pm ET
Algernon (AGN) has submitted a meeting request to the FDA for its DMT clinical stroke research program.
Algernon seeks to investigate AP-188, or DMT, a known psychedelic tryptamine compound, as a treatment of stroke-related dysfunctions. In the meeting request application, Algernon is seeking direction regarding the use of DMT as an adjunctive treatment with constraint-induced movement therapy for upper-limb dysfunction in stroke patients.
CIMT is a form of physical therapy that involves intensive training of the weaker limb while restricting the use of the stronger limb. It has demonstrated the ability to enhance recovery after a stroke.
The company plans to evaluate whether adding DMT treatment to CIMT results in increased neuroplasticity, thereby enhancing the effects of physical therapy.
The company’s decision to investigate DMT is based on multiple independent, positive preclinical studies demonstrating that DMT helps promote neurogenesis, as well as structural and functional neuroplasticity.
Algernon has filed provisional patents for new forms of DMT in addition to formulation, dosage and method of use claims for ischemic stroke. The company has also filed claims for combination therapy between DMT and CIMT.
Algernon has contracted Dalton Pharma Services to manufacture the active pharmaceutical ingredient and finished product for its formulation of DMT, Charles River Laboratories to conduct its preclinical studies of DMT, and Hammersmith Medicines Research to conduct its DMT Phase 1 study.
Another meeting request for the use of DMT as a treatment for acute stroke will be filed once the company completes the requisite preclinical work.
Algernon is a drug re-purposing company that investigates already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
Algernon Pharmaceuticals (AGN) is up 6.35 per cent, trading at C$0.335 per share as of 1:25 pm ET.
